AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis

Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis[1-8] The New Drug Application (NDA) is supported by data from the global upadaci... Biopharmaceuticals, FDA AbbVie, Upadacitinib, Rheumatoid Arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news